Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory study of NS 065/NCNP 01 in Duchenne muscular dystrophy

Next Previous
Trial Profile

Exploratory study of NS 065/NCNP 01 in Duchenne muscular dystrophy

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Viltolarsen (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; First in man; Registrational
  • Sponsors Nippon Shinyaku

    • Most Recent Events

    • 13 Aug 2020 According to an Nippon Shinyaku media release, the U.S. Food & Drug Administration (FDA) has approved VILTEPSO (viltolarsen) injection for patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping therapy. DMD is a progressive muscle disease that primarily occurs in boys due to a genetic mutation in the dystrophin gene.
    • 19 Apr 2018 According to a Nippon Shinyaku media release, registry of Muscular Dystrophy (Remudy) was utilized for patient recruitment in The Study.
    • 19 Apr 2018 Results published in the Nippon Shinyaku Media Release
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top